Product Information
CARBIDOPA-LEVO 25-100 MG ODT is a generic product labeled by Rising Pharma Holdings Inc., priced at $0.6865 per EA under NDC 16571015801. Its NADAC has been published 36 times since Jan 28, 2026.
FDA first approved this application on Sep 18, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the carbidopa and levodopa market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
25; 100 mg/1; mg/1
Manufacturer
Rising Pharma Holdings Inc.NDC
16571015801
Classification
Generic
Dosage Form
TABLET, ORALLY DISINTEGRATING
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CARBIDOPA; LEVODOPAApproval Type
Generic (ANDA)
FDA Application
ANDA078893FDA Approved
9/18/2008
TE Code
AB
On Market Since
1/8/2025
Pharmacological Classes
Price Statistics
The NADAC for CARBIDOPA-LEVO 25-100 MG ODT has been published 36 times since Jan 28, 2026, and over the history we have for it it has declined 9.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.6865 per EA |
|---|---|
| All-time high | $0.7612 (Feb 11, 2026) |
| All-time low | $0.6865 (Sep 23, 2026) |
| 52-week high | $0.7612 |
| 52-week low | $0.6865 |
| Median price | $0.7295 |
| Average price | $0.7287 |
| Largest weekly change | -2.2% (Apr 22, 2026) |
| Weeks tracked | 36 |
| Tracking since | Jan 28, 2026 |
Generic Alternatives
The matcher finds 5 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 89% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Rising Pharma Holdings Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
carbidopa and levodopa market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Aromatic Amino Acid class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CARBIDOPA-LEVO 25-100 MG ODT?
The current National Average Drug Acquisition Cost (NADAC) for CARBIDOPA-LEVO 25-100 MG ODT, manufactured by Rising Pharma Holdings Inc., is $0.6865 per EA (NDC 16571015801), effective Sep 30, 2026.
How has the price of CARBIDOPA-LEVO 25-100 MG ODT changed over time?
Over the history we have for it, the NADAC for CARBIDOPA-LEVO 25-100 MG ODT has declined 9.8%. It has been tracked across 36 weekly CMS publications since Jan 28, 2026.
What are the highest and lowest recorded NADAC prices for CARBIDOPA-LEVO 25-100 MG ODT?
Since Jan 28, 2026, the NADAC for CARBIDOPA-LEVO 25-100 MG ODT has ranged from a low of $0.6865 (Sep 23, 2026) to a high of $0.7612 (Feb 11, 2026), with a median of $0.7295 per EA.
Are there cheaper alternatives to CARBIDOPA-LEVO 25-100 MG ODT?
Yes. 5 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, CARBIDOPA-LEVODOPA 25-100 TAB, is $0.0724 per EA — about 89% below CARBIDOPA-LEVO 25-100 MG ODT.
Who manufactures CARBIDOPA-LEVO 25-100 MG ODT?
CARBIDOPA-LEVO 25-100 MG ODT (NDC 16571015801) is labeled by Rising Pharma Holdings Inc., and CMS classifies it as a generic product.